Study S001220

A Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06256549
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 272
Start: 2023-08-09
Primary completion: 2024-07-20
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Type 2 Diabetes
Interventions: DRUG:GZR18; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks [24 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002218	Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial. Liu M, Annals of internal medicine	2026	Randomized trial	PMID 42372276 DOI	cites ClinicalTrials.gov:NCT06256549; registry reference DERIVED:42372276